1316MO BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study

Li Zhang, Yuxiang Ma, Yuanyuan Zhao, Wenfeng Fang, Hongyun Zhao, Yan Huang, Yunpeng Yang, Xue Hou, Zhongyuan Wen, Shuang Zhang, Jing Wang, S. Xiao, H. Wang, Hai‐Dong Zhu, Martin Olivo, Yao Zhu